{"id":355499,"date":"2026-11-19T15:09:27","date_gmt":"2026-11-19T09:39:27","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355499"},"modified":"2026-11-19T15:09:27","modified_gmt":"2026-11-19T09:39:27","slug":"alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/","title":{"rendered":"Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Alembic_Pharma_Share_Price_123_CAGR_in_3_Years_as_the_Vadodara-Based_Drug_Maker_Compares_With_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals\" title=\"Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals\">Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_Much_Has_the_Alembic_Pharma_Share_Price_Returned_in_3_Years\" title=\"How Much Has the Alembic Pharma Share Price Returned in 3 Years?\">How Much Has the Alembic Pharma Share Price Returned in 3 Years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Alembic_Pharma_vs_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals_3-Year_CAGR_Compared\" title=\"Alembic Pharma vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared\">Alembic Pharma vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Valuation_and_Quality_Compared\" title=\"Valuation and Quality Compared\">Valuation and Quality Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_Is_Driving_the_Alembic_Pharma_Stock\" title=\"What Is Driving the Alembic Pharma Stock?\">What Is Driving the Alembic Pharma Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_the_Established_Players_Stack_Up\" title=\"How the Established Players Stack Up\">How the Established Players Stack Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_Should_Investors_Track_Next\" title=\"What Should Investors Track Next?\">What Should Investors Track Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_to_Compare_Pharma_Stocks_Yourself\" title=\"How to Compare Pharma Stocks Yourself\">How to Compare Pharma Stocks Yourself<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#A_Low-Multiple_Drug_Maker_Beside_Three_Larger_Peers\" title=\"A Low-Multiple Drug Maker Beside Three Larger Peers\">A Low-Multiple Drug Maker Beside Three Larger Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_is_the_Alembic_Pharma_share_price_today\" title=\"What is the Alembic Pharma share price today?\">What is the Alembic Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_is_the_3-year_CAGR_of_the_Alembic_Pharma_stock\" title=\"What is the 3-year CAGR of the Alembic Pharma stock?\">What is the 3-year CAGR of the Alembic Pharma stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Is_Alembic_Pharma_better_than_Lupin\" title=\"Is Alembic Pharma better than Lupin?\">Is Alembic Pharma better than Lupin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#What_does_Alembic_Pharmaceuticals_do\" title=\"What does Alembic Pharmaceuticals do?\">What does Alembic Pharmaceuticals do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Is_the_Alembic_Pharma_stock_debt_free\" title=\"Is the Alembic Pharma stock debt free?\">Is the Alembic Pharma stock debt free?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Is_Alembic_Pharma_expensive_compared_with_the_industry\" title=\"Is Alembic Pharma expensive compared with the industry?\">Is Alembic Pharma expensive compared with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#Which_pharma_stock_gave_the_highest_return_in_3_years\" title=\"Which pharma stock gave the highest return in 3 years?\">Which pharma stock gave the highest return in 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-3-year-cagr-vs-pharma-peers-zydus-lupin-glenmark\/#How_do_I_calculate_CAGR_for_a_stock\" title=\"How do I calculate CAGR for a stock?\">How do I calculate CAGR for a stock?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Alembic_Pharma_Share_Price_123_CAGR_in_3_Years_as_the_Vadodara-Based_Drug_Maker_Compares_With_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals\"><\/span><strong>Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Alembic Pharma previous close Rs 1,044.35. 3-year CAGR 12.3%. Up 1.4x since 17 Nov 2023. ROE 14.20%. Market cap Rs 20,512 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Alembic Pharma share price<\/strong> closed at Rs 1,044.35 on 18 November 2026, a compounded annual return of <strong>12.3%<\/strong> over three years. That compares with Zydus Lifesciences at 23.6%, Lupin at 18.1% and Glenmark Pharmaceuticals at 50.5%. The company has a <strong>market cap<\/strong> of Rs 20,512 crore and a P\/E of 24.43 against an industry P\/E of 40.12.<\/p>\n<\/p><\/div>\n<p>The <strong>Alembic Pharma share price<\/strong> closed at Rs 1,044.35 on 18 November 2026 and has compounded at <strong>12.3%<\/strong> a year over three years. Alembic Pharmaceuticals, based in Vadodara, makes <strong>generic medicines<\/strong>, specialty drugs and active ingredients for India and export markets.<\/p>\n<p>This article places that return beside Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals. We calculate the <strong>three-year CAGR<\/strong> for all four and set the results next to market cap, valuation, <strong>return on equity<\/strong> and debt, using prices adjusted for corporate actions.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=alembic-pharma-share-price\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_the_Alembic_Pharma_Share_Price_Returned_in_3_Years\"><\/span><strong>How Much Has the Alembic Pharma Share Price Returned in 3 Years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alembic Pharma stock closed at Rs 737.30 on 17 November 2023 and at Rs 1,044.35 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.42 lakh, which is a <strong>CAGR<\/strong> of <strong>12.3%<\/strong>. This is a price return and leaves out dividends.<\/p>\n<p>CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Alembic Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.<\/p>\n<p>Pharma shares move with product launches, approvals and currency, so a three-year window captures several cycles. The <strong>Alembic Pharma share price<\/strong> has risen steadily while its valuation stayed below the sector average.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharma_vs_Zydus_Lifesciences_Lupin_and_Glenmark_Pharmaceuticals_3-Year_CAGR_Compared\"><\/span><strong>Alembic Pharma vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Close on 17 Nov 2023<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Previous close (18 Nov 2026)<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Price multiple<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">3-year CAGR<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Glenmark Pharmaceuticals<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 775.95<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 2,646.10<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">3.4x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">50.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 636.55<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,202.00<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.9x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">23.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Lupin<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,196.30<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,971.90<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.6x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Alembic Pharmaceuticals<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 737.30<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,044.35<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.4x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">12.3%<\/td>\n<\/tr>\n<\/table>\n<p>The Alembic Pharma stock ranks fourth of the four at <strong>12.3%<\/strong>. The companies ahead are Glenmark Pharmaceuticals (50.5%), Zydus Lifesciences (23.6%) and Lupin (18.1%). By market cap the company ranks fourth of the four at Rs 20,512 crore. Zydus Lifesciences is the largest of the four by market cap, so Alembic is the smallest company in this group.<\/p>\n<p>Look at the <strong>Alembic Pharma share price<\/strong> alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Quality_Compared\"><\/span><strong>Valuation and Quality Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Market cap<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Debt to equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,19,202 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">27.71<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">15.10%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 90,039 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.24<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">21.65%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.26<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 74,931 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">51.63<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.07%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.13<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 20,512 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">24.43<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.12<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">14.20%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.26<\/td>\n<\/tr>\n<\/table>\n<p>By market cap, Zydus Lifesciences is the largest of the group at Rs 1,19,202 crore, while the Alembic Pharma stock stands at Rs 20,512 crore, about 17% of that size. On earnings, Alembic Pharma shares trade at a P\/E of 24.43 against an industry P\/E of 40.12, a discount of about 39% to the sector, which leaves room if earnings keep growing. Peer multiples are Zydus Lifesciences at 27.71, Lupin at 17.24 and Glenmark Pharmaceuticals at 51.63.<\/p>\n<p>Return on equity is 14.20% for the Alembic Pharma stock, which ranks fourth among the four, and <strong>debt to equity<\/strong> stands at 0.26. Trailing EPS is Rs 42.72. Alembic trades at a P\/E of 24.43 against an industry P\/E of 40.12, with a price to book of 3.45. That is the second lowest P\/E in the group, so the market asks less for each rupee of earnings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Alembic_Pharma_Stock\"><\/span><strong>What Is Driving the Alembic Pharma Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alembic sells generic formulations in the United States and India, along with specialty products and <strong>active pharmaceutical ingredients<\/strong>. The mix gives it exposure to both regulated export markets and the domestic branded market.<\/p>\n<p>The company earns an ROE of 14.20% and carries a debt to equity of 0.26, which is the second highest in the group. Its P\/E of 24.43 sits well below the industry P\/E of 40.12.<\/p>\n<p>Investors who follow the <strong>Alembic Pharma share price<\/strong> usually track US generic launches, India sales growth, plant approvals and quarterly operating margin.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_the_Established_Players_Stack_Up\"><\/span><strong>How the Established Players Stack Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences is an Ahmedabad-based drug maker with generics, branded medicines and a vaccines business. It compounded at 23.6% a year, on a market cap of Rs 1,19,202 crore and an ROE of 15.10%.<\/p>\n<p>Lupin is a Mumbai-based drug maker with a strong presence in respiratory and cardiovascular medicines. It compounded at 18.1% a year, on a market cap of Rs 90,039 crore and an ROE of 21.65%.<\/p>\n<p>Glenmark Pharmaceuticals is a Mumbai-based drug maker with a presence in dermatology and respiratory therapies. It compounded at 50.5% a year, on a market cap of Rs 74,931 crore and an ROE of 18.07%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Track_Next\"><\/span><strong>What Should Investors Track Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three things are worth watching on the <strong>Alembic Pharma share price<\/strong>. First, product launches and approvals in the United States. Second, growth in the India business. Third, operating margin in the next quarterly result.<\/p>\n<p>At a P\/E of 24.43 the stock trades well below the industry P\/E of 40.12, which leaves room if earnings keep growing. US pricing can change quickly, so follow each result closely.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals of pharma stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Pharma_Stocks_Yourself\"><\/span><strong>How to Compare Pharma Stocks Yourself<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can repeat this exercise for any pair of stocks, including the Alembic Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P\/E against the industry P\/E, ROE and debt to equity. Benchmark the result against the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> as well, so you know whether the stock beat the broader market.<\/p>\n<p>A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the <strong>Alembic Pharma share price<\/strong>, the same four checks give a more complete picture than price alone.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the <strong>Alembic Pharma share price<\/strong> and compare pharma stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"A_Low-Multiple_Drug_Maker_Beside_Three_Larger_Peers\"><\/span><strong>A Low-Multiple Drug Maker Beside Three Larger Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alembic Pharma share price<\/strong> compounded at 12.3% a year over three years, against 50.5% for Glenmark, 23.6% for Zydus and 18.1% for Lupin. It trades at a P\/E of 24.43, against an industry P\/E of 40.12.<\/p>\n<p>Glenmark Pharmaceuticals brings the fastest return, Lupin brings the highest ROE and Lupin brings the lowest P\/E. Alembic has a smaller market cap than the other three and a P\/E well below the industry average.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alembic_Pharma_share_price_today\"><\/span><strong>What is the Alembic Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals closed at Rs 1,044.35 on 18 November 2026, according to NSE data. It has a market cap of Rs 20,512 crore and a P\/E of 24.43. Check live quotes before acting, as prices change every trading day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_3-year_CAGR_of_the_Alembic_Pharma_stock\"><\/span><strong>What is the 3-year CAGR of the Alembic Pharma stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals delivered a price CAGR of 12.3% over three years, moving from Rs 737.30 on 17 November 2023 to Rs 1,044.35 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharma_better_than_Lupin\"><\/span><strong>Is Alembic Pharma better than Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin delivered the higher three-year CAGR at 18.1% against 12.3% for Alembic Pharma. Lupin has the larger market cap at Rs 90,039 crore against Rs 20,512 crore for Alembic Pharma. Lupin earns the higher ROE at 21.65% against 14.20%. Lupin trades at the lower P\/E of 17.24 against 24.43. The better choice depends on whether you weigh recent return, size, profitability or valuation most.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Alembic_Pharmaceuticals_do\"><\/span><strong>What does Alembic Pharmaceuticals do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals Limited is a Vadodara-based pharmaceutical company that makes generic medicines, specialty drugs and active ingredients for India and global markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Alembic_Pharma_stock_debt_free\"><\/span><strong>Is the Alembic Pharma stock debt free?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio of the Alembic Pharma stock is 0.26 and its return on equity is 14.20%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharma_expensive_compared_with_the_industry\"><\/span><strong>Is Alembic Pharma expensive compared with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharma trades at a P\/E of 24.43 against an industry P\/E of 40.12. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_gave_the_highest_return_in_3_years\"><\/span><strong>Which pharma stock gave the highest return in 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the companies compared here, Glenmark Pharmaceuticals delivered the highest three-year CAGR at 50.5%, followed by Zydus Lifesciences at 23.6%. Past returns do not guarantee future performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_calculate_CAGR_for_a_stock\"><\/span><strong>How do I calculate CAGR for a stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Alembic Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alembic Pharmaceuticals closed at Rs 1,044.35 on 18 November 2026, according to NSE data. It has a market cap of Rs 20,512 crore and a P\/E of 24.43. Check live quotes before acting, as prices change every trading day.\"}},{\"@type\":\"Question\",\"name\":\"What is the 3-year CAGR of the Alembic Pharma stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alembic Pharmaceuticals delivered a price CAGR of 12.3% over three years, moving from Rs 737.30 on 17 November 2023 to Rs 1,044.35 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Is Alembic Pharma better than Lupin?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin delivered the higher three-year CAGR at 18.1% against 12.3% for Alembic Pharma. Lupin has the larger market cap at Rs 90,039 crore against Rs 20,512 crore for Alembic Pharma. Lupin earns the higher ROE at 21.65% against 14.20%. Lupin trades at the lower P\/E of 17.24 against 24.43. The better choice depends on whether you weigh recent return, size, profitability or valuation most.\"}},{\"@type\":\"Question\",\"name\":\"What does Alembic Pharmaceuticals do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alembic Pharmaceuticals Limited is a Vadodara-based pharmaceutical company that makes generic medicines, specialty drugs and active ingredients for India and global markets.\"}},{\"@type\":\"Question\",\"name\":\"Is the Alembic Pharma stock debt free?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio of the Alembic Pharma stock is 0.26 and its return on equity is 14.20%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.\"}},{\"@type\":\"Question\",\"name\":\"Is Alembic Pharma expensive compared with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Alembic Pharma trades at a P\/E of 24.43 against an industry P\/E of 40.12. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock gave the highest return in 3 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the companies compared here, Glenmark Pharmaceuticals delivered the highest three-year CAGR at 50.5%, followed by Zydus Lifesciences at 23.6%. Past returns do not guarantee future performance.\"}},{\"@type\":\"Question\",\"name\":\"How do I calculate CAGR for a stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharma share price compounded at 12.3% a year over 3 years. See how it compares with peers on returns and valuation.<\/p>\n","protected":false},"author":35,"featured_media":355498,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[26369,26370,26371,19413],"class_list":["post-355499","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-alembic-pharma-share-price","tag-alembic-pharma-vs-lupin","tag-alembic-pharmaceuticals-stock","tag-pharma-stocks-3-year-return"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355498"],"rank_math_title":["Alembic Pharma Share Price: 12.3% CAGR vs Zydus, Lupin"],"rank_math_description":["Alembic Pharma share price compounded at 12.3% a year over 3 years. See how it compares with peers on returns and valuation."],"rank_math_focus_keyword":["Alembic Pharma share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/alembic-pharma-share-price-12-3-cagr-in-3-years-as-the-vadodara-based-drug-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355499"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355499\/revisions"}],"predecessor-version":[{"id":355500,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355499\/revisions\/355500"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355498"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}